Semaglutide biosimilar - Hangzhou Jiuyuan Gene Engineering
Latest Information Update: 15 Oct 2024
Price :
$50 *
At a glance
- Originator Hangzhou Jiuyuan Gene Engineering
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 09 Oct 2024 Hangzhou Jiuyuan Gene Engineering plans a phase III trial for Obesity in China (SC) (NCT06633783)
- 31 Oct 2023 Hangzhou Jiuyuan Gene Engineering completes the phase III trial in Type 2 Diabetes mellitus (combination therapy) in China (NCT05816057)
- 25 Jul 2022 Phase-III clinical trials in Type 2 diabetes mellitus (Combination therapy) in China (SC) (NCT05816057)